Genome-wide association for smoking cessation success in a trial of precessation nicotine replacement.
- Authors
- Uhl, George R; Drgon, Tomas; Johnson, Catherine; Ramoni, Marco F; Behm, Frederique M; Rose, Jed E
- Year
- 2010
- Journal
- Molecular medicine (Cambridge, Mass.)
- PMID
- 20811658
- DOI
- 10.2119/molmed.2010.00052
- PMCID
- PMC2972392
Abilities to successfully quit smoking display substantial evidence for heritability in classic and molecular genetic studies. Genome-wide association (GWA) studies have demonstrated single-nucleotide polymorphisms (SNPs) and haplotypes that distinguish successful quitters from individuals who were unable to quit smoking in clinical trial participants and in community samples. Many of the subjects in these clinical trial samples were aided by nicotine replacement therapy (NRT). We now report novel GWA results from participants in a clinical trial that sought dose/response relationships for "precessation" NRT. In this trial, 369 European-American smokers were randomized to 21 or 42 mg NRT, initiated 2 wks before target quit dates. Ten-week continuous smoking abstinence was assessed on the basis of self-reports and carbon monoxide levels. SNP genotyping used Affymetrix 6.0 arrays. GWA results for smoking cessation success provided no P value that reached "genome-wide" significance. Compared with chance, these results do identify (a) more clustering of nominally positive results within small genomic regions, (b) more overlap between these genomic regions and those identified in six prior successful smoking cessation GWA studies and (c) sets of genes that fall into gene ontology categories that appear to be biologically relevant. The 1,000 SNPs with the strongest associations form a plausible Bayesian network; no such network is formed by randomly selected sets of SNPs. The data provide independent support, based on individual genotyping, for many loci previously nominated on the basis of data from genotyping in pooled DNA samples. These results provide further support for the idea that aid for smoking cessation may be personalized on the basis of genetic predictors of outcome.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. | Cinciripini PM et al. | — | 2024 | → |
| Efficacy of bupropion and varenicline genetic markers in choosing pharmacological treatment for smoking cessation, and implications for combining drugs: A randomized controlled trial - GENTSMOKING. | Gaya PV et al. | — | 2024 | → |
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | — | 2023 | → |
| Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. | Theodoulou A et al. | — | 2023 | → |
| Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment. | Chen LS et al. | — | 2023 | → |
| Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D. | Uhl GR | — | 2023 | → |
| A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation. | Jones SK et al. | — | 2022 | → |
| Behavioral and Genetic Factors Associated with Successful Long-Term Cessation in Persons with HIV Who Smoke Cigarettes. | Shuter J et al. | — | 2021 | → |
| LAR Receptor Tyrosine Phosphatase Family in Healthy and Diseased Brain. | Cornejo F et al. | — | 2021 | → |
| The Streetlight Effect: Reappraising the Study of Addiction in Light of the Findings of Genome-wide Association Studies. | Hall FS et al. | — | 2020 | → |
| Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. | Lindson N et al. | — | 2019 | → |
| Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. | West R et al. | — | 2018 | → |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. | Salloum NC et al. | — | 2018 | → |
| Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How. | Chen LS et al. | — | 2018 | → |
| Pathways to precision medicine in smoking cessation treatments. | Chen LS et al. | — | 2018 | → |
| Polygenic Score × Intervention Moderation: an Application of Discrete-Time Survival Analysis to Model the Timing of First Marijuana Use Among Urban Youth. | Musci RJ et al. | — | 2018 | → |
| The Role of Cell Adhesion Molecule Genes Regulating Neuroplasticity in Addiction. | Muskiewicz DE et al. | — | 2018 | → |
| Alpha-1 antitrypsin inhibits RANKL-induced osteoclast formation and functions. | Akbar MA et al. | — | 2017 | → |
| Pathways to smoking behaviours: biological insights from the Tobacco and Genetics Consortium meta-analysis. | Minicã CC et al. | — | 2017 | → |
| Cadherin 13: human <i>cis</i>-regulation and selectively-altered addiction phenotypes and cerebral cortical dopamine in knockout mice. | Drgonova J et al. | — | 2016 | → |
| Validity of using ad hoc methods to analyze secondary traits in case-control association studies. | Yung G et al. | — | 2016 | → |
| Altered CSMD1 Expression Alters Cocaine-Conditioned Place Preference: Mutual Support for a Complex Locus from Human and Mouse Models. | Drgonova J et al. | — | 2015 | → |
| Associations between the orexin (hypocretin) receptor 2 gene polymorphism Val308Ile and nicotine dependence in genome-wide and subsequent association studies. | Nishizawa D et al. | — | 2015 | → |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | — | 2015 | → |
| Human cell adhesion molecules: annotated functional subtypes and overrepresentation of addiction-associated genes. | Zhong X et al. | — | 2015 | → |
| Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. | Tyndale RF et al. | — | 2015 | → |
| Mouse Model for Protein Tyrosine Phosphatase D (<i>PTPRD</i>) Associations with Restless Leg Syndrome or Willis-Ekbom Disease and Addiction: Reduced Expression Alters Locomotion, Sleep Behaviors and Cocaine-Conditioned Place Preference. | Drgonova J et al. | — | 2015 | → |
| Polygenic score × intervention moderation: an application of discrete-time survival analysis to modeling the timing of first tobacco use among urban youth. | Musci RJ et al. | — | 2015 | → |
| Axonal guidance signaling pathway interacting with smoking in modifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS data. | Tang H et al. | — | 2014 | → |
| Curious cases: Altered dose-response relationships in addiction genetics. | Uhl GR et al. | — | 2014 | → |
| Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. | Uhl GR et al. | — | 2014 | → |
| A genomewide association study of smoking relapse in four European population-based samples. | Tozzi F et al. | — | 2013 | → |
| Environmental and genomic factors as well as interventions influencing smoking cessation: a systematic review of reviews and a proposed working model. | de Viron S et al. | — | 2013 | → |
| Genome-wide association study of a quantitative disordered gambling trait. | Lind PA et al. | — | 2013 | → |
| Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? | Hall FS et al. | — | 2013 | → |
| Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. | David SP et al. | — | 2013 | → |
| Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. | Bruehl S et al. | — | 2013 | → |
| A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation. | Verhagen M et al. | — | 2012 | → |
| Genotype×age interaction in human transcriptional ageing. | Kent JW et al. | — | 2012 | → |
| Large-scale genome-wide association study of Asian population reveals genetic factors in FRMD4A and other loci influencing smoking initiation and nicotine dependence. | Yoon D et al. | — | 2012 | → |
| Mouse models for studying genetic influences on factors determining smoking cessation success in humans. | Hall FS et al. | — | 2012 | → |
| Nicotine replacement therapy for smoking cessation. | Stead LF et al. | — | 2012 | → |
| The CHRNA5-A3-B4 gene cluster in nicotine addiction. | Berrettini WH et al. | — | 2012 | → |
| Genome-wide association scan for survival on dialysis in African-Americans with type 2 diabetes. | Murea M et al. | — | 2011 | → |
| Individualized smoking cessation treatment: roles for sets of genomic markers. | Uhl GR et al. | — | 2011 | → |
| Marco Ramoni: an appreciation of academic achievement. | Kohane IS et al. | — | 2011 | → |
| The galanin receptor 1 gene associates with tobacco craving in smokers seeking cessation treatment. | Lori A et al. | — | 2011 | → |